霉酚酸酯用于治疗对熊去氧胆酸反应不完全的原发性胆汁性肝硬化患者。 - Suppr

Suppr

超能文献

Mycophenolate mofetil for the treatment of primary biliary cirrhosis in patients with an incomplete response to ursodeoxycholic acid.

作者信息

Treiber Gerhard, Malfertheiner Peter

出版信息

J Clin Gastroenterol. 2005 Oct;39(9):837-8; author reply 838. doi: 10.1097/01.mcg.0000177235.36640.21.

DOI:10.1097/01.mcg.0000177235.36640.21

PMID:16145353

Abstract

摘要

相似文献

Mycophenolate mofetil for the treatment of primary biliary cirrhosis in patients with an incomplete response to ursodeoxycholic acid.霉酚酸酯用于治疗对熊去氧胆酸反应不完全的原发性胆汁性肝硬化患者。

J Clin Gastroenterol. 2005 Oct;39(9):837-8; author reply 838. doi: 10.1097/01.mcg.0000177235.36640.21.

Mycophenolate mofetil for primary biliary cirrhosis--convergent thinking.

Eur J Gastroenterol Hepatol. 2000 May;12(5):587.

J Clin Gastroenterol. 2005 Feb;39(2):168-71.

Triple therapy for patients with primary biliary cirrhosis with progressive disease despite ursodeoxycholic acid: another step forward.

Gastroenterol Clin Biol. 2010 Apr-May;34(4-5):239-41. doi: 10.1016/j.gcb.2010.03.013. Epub 2010 May 11.

Pilot study: fenofibrate for patients with primary biliary cirrhosis and an incomplete response to ursodeoxycholic acid.初步研究：非诺贝特治疗对熊去氧胆酸应答不完全的原发性胆汁性肝硬化患者。

Aliment Pharmacol Ther. 2011 Jan;33(2):235-42. doi: 10.1111/j.1365-2036.2010.04512.x. Epub 2010 Nov 17.

Combination therapy with mycophenolate mofetil and ursodeoxycholic acid for primary biliary cirrhosis.

Eur J Gastroenterol Hepatol. 1999 Oct;11(10):1165-9.

Ursodeoxycholic acid for the treatment of primary biliary cirrhosis.熊去氧胆酸用于治疗原发性胆汁性肝硬化。

N Engl J Med. 2007 Oct 11;357(15):1524-9. doi: 10.1056/NEJMct074694.

[Cholestatic liver diseases--diagnosis and therapy. 3: Therapy of primary biliary cirrhosis].[胆汁淤积性肝病——诊断与治疗。3：原发性胆汁性肝硬化的治疗]

Fortschr Med. 1998 Jan 20;116(1-2):37-9.

Triple therapy with ursodeoxycholic acid, budesonide and mycophenolate mofetil in patients with features of severe primary biliary cirrhosis not responding to ursodeoxycholic acid alone.

Gastroenterol Clin Biol. 2010 Apr-May;34(4-5):283-7. doi: 10.1016/j.gcb.2010.02.004. Epub 2010 Apr 22.

The combination of ursodeoxycholic acid and methotrexate for primary biliary cirrhosis is not better than ursodeoxycholic acid alone.熊去氧胆酸与甲氨蝶呤联合用于原发性胆汁性肝硬化并不比单独使用熊去氧胆酸效果更好。

J Hepatol. 1997 Jul;27(1):143-9. doi: 10.1016/s0168-8278(97)80294-2.

引用本文的文献

Clinical management of autoimmune liver diseases: juncture, opportunities, and challenges ahead.自身免疫性肝病的临床管理：当前的节点、机遇与挑战

Immunol Res. 2025 Apr 7;73(1):67. doi: 10.1007/s12026-025-09622-9.

The Management of Cholestatic Liver Diseases: Current Therapies and Emerging New Possibilities.胆汁淤积性肝病的管理：当前疗法与新出现的可能性

J Clin Med. 2021 Apr 18;10(8):1763. doi: 10.3390/jcm10081763.

New Therapeutic Targets in Autoimmune Cholangiopathies.自身免疫性胆管病的新治疗靶点

Front Med (Lausanne). 2020 Apr 7;7:117. doi: 10.3389/fmed.2020.00117. eCollection 2020.

Proposed therapies in primary biliary cholangitis.原发性胆汁性胆管炎的推荐疗法。

Expert Rev Gastroenterol Hepatol. 2016;10(3):371-382. doi: 10.1586/17474124.2016.1121810. Epub 2016 Jan 6.

Advances in pharmacotherapy for primary biliary cirrhosis.原发性胆汁性肝硬化药物治疗的进展

Expert Opin Pharmacother. 2015 Apr;16(5):633-43. doi: 10.1517/14656566.2015.998650. Epub 2014 Dec 29.

A case of primary biliary cirrhosis that progressed rapidly after treatment involving rituximab.一例在使用利妥昔单抗治疗后迅速进展的原发性胆汁性肝硬化病例。

Case Rep Gastroenterol. 2013 Apr 19;7(1):195-201. doi: 10.1159/000351173. Print 2013 Jan.

Biochemical and immunologic effects of rituximab in patients with primary biliary cirrhosis and an incomplete response to ursodeoxycholic acid.利妥昔单抗治疗原发性胆汁性肝硬化患者对熊去氧胆酸应答不完全的生化和免疫效应。

Hepatology. 2012 Feb;55(2):512-21. doi: 10.1002/hep.24748.

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验